enfortumab
Phase III Study: Perioperative Padcev & Keytruda Combo Significantly Improves Survival in Bladder Cancer
Padcev; Keytruda; enfortumab vedotin; pembrolizumab; phase III; bladder cancer; muscle-invasive bladder cancer; cisplatin-ineligible; perioperative; event-free survival; overall survival